Search Here

In a new study, scientists find a link between a blood pressure drug as well as Alzheimer's disease, according to a study published in the journal Alzheimer's Research and Therapy

The most common kind of dementia or a decline in mental ability disrupting everyday life include behavioral health issues, according to scienceworldreport.

The FDA-approved drug called candesartan can bring down cell damage that is often linked to Alzheimer's, say researchers at Georgetown University Medical Center (GUMC) and the National Institutes of Health. "Our findings make sense in many ways," said the senior study author Juan M. Saavedra, MD, from GUMC's Department of Pharmacology and Physiology, in a news release. "Hypertension reduces blood flow throughout the body and brain and is a risk factor for Alzheimer's disease. Previous epidemiological studies found that Alzheimer's progression is delayed in hypertensive patients treated with ARBs."

Through an in-depth gene analysis of laboratory results, it was seen that candesartan helped to prevent neuronal inflammation and related pathological procedures, which included changes in the amyloid metabolism. This was a highlight of the ailment.

Scientists then compared gene expression in neuronal cultures with published gene databases of autopsy samples from patients suffering from Alzheimer's disease.

"The correlations were impressive -- the expression of 471 genes that were altered by excess glutamate in our cultures were also altered in brain autopsy samples from patients who suffered from Alzheimer's disease. Candesartan normalized expression of these genes in our cultures," said first study author Abdel G. Elkahloun, Ph.D., from the Comparative Genomics and Cancer Genetics Branch of the National Human Genome Research Institute.